MA49625A - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques

Info

Publication number
MA49625A
MA49625A MA049625A MA49625A MA49625A MA 49625 A MA49625 A MA 49625A MA 049625 A MA049625 A MA 049625A MA 49625 A MA49625 A MA 49625A MA 49625 A MA49625 A MA 49625A
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
MA049625A
Other languages
English (en)
Inventor
Matthew Carl Allgeier
Tony Yantao Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA49625A publication Critical patent/MA49625A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA049625A 2017-07-17 2018-07-10 Compositions pharmaceutiques MA49625A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533332P 2017-07-17 2017-07-17
US201762538936P 2017-07-31 2017-07-31

Publications (1)

Publication Number Publication Date
MA49625A true MA49625A (fr) 2020-05-27

Family

ID=63036446

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049625A MA49625A (fr) 2017-07-17 2018-07-10 Compositions pharmaceutiques

Country Status (24)

Country Link
US (2) US11376223B2 (fr)
EP (1) EP3654955A1 (fr)
JP (1) JP6854384B2 (fr)
KR (1) KR102409102B1 (fr)
CN (1) CN110913843B (fr)
AU (1) AU2018301924B2 (fr)
BR (1) BR112019028278A2 (fr)
CA (1) CA3069948C (fr)
CL (1) CL2020000120A1 (fr)
CO (1) CO2019015099A2 (fr)
CR (1) CR20190577A (fr)
DO (1) DOP2020000010A (fr)
EC (1) ECSP20003493A (fr)
IL (1) IL272044A (fr)
JO (1) JOP20200005A1 (fr)
MA (1) MA49625A (fr)
MY (1) MY198062A (fr)
PE (1) PE20200174A1 (fr)
PH (1) PH12020500120A1 (fr)
SA (1) SA520410976B1 (fr)
SG (1) SG11201912482WA (fr)
UA (1) UA125535C2 (fr)
WO (1) WO2019018155A1 (fr)
ZA (1) ZA201908550B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102409102B1 (ko) * 2017-07-17 2022-06-16 일라이 릴리 앤드 캄파니 제약 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4083818B2 (ja) 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
AU736951C (en) 1998-03-19 2003-02-20 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
CN1688341A (zh) * 2002-08-08 2005-10-26 三共株式会社 降低血脂的药物组合物
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
SI2120878T1 (sl) 2007-02-09 2014-12-31 Alphapharm Pty Ltd Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah
EP2167048B1 (fr) * 2007-05-30 2016-10-26 Wockhardt Limited Nouvelle forme posologique de comprimé
MX2013000824A (es) 2010-07-21 2013-10-28 Nucitec Sa De Cv Forma de dosificacion diaria unica para la prevencion y tratamiento del sindrome metabolico.
US9572784B2 (en) * 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
HUE030674T2 (en) * 2012-03-30 2017-06-28 Dae Woong Pharma A pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or a salt thereof
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
BR102013028883A2 (pt) 2013-11-08 2015-10-06 Hypermarcas S A forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica
WO2016040462A2 (fr) 2014-09-09 2016-03-17 ARKAY Therapeutics, LLC Formulations et méthodes de traitement du syndrome métabolique
KR102409102B1 (ko) * 2017-07-17 2022-06-16 일라이 릴리 앤드 캄파니 제약 조성물

Also Published As

Publication number Publication date
NZ760868A (en) 2023-09-29
US11376223B2 (en) 2022-07-05
ECSP20003493A (es) 2020-08-31
CO2019015099A2 (es) 2020-01-17
JP2020527147A (ja) 2020-09-03
PE20200174A1 (es) 2020-01-24
US20220287978A1 (en) 2022-09-15
KR20200015758A (ko) 2020-02-12
MY198062A (en) 2023-07-31
US11918692B2 (en) 2024-03-05
JP6854384B2 (ja) 2021-04-07
CA3069948C (fr) 2022-05-17
AU2018301924B2 (en) 2021-07-29
ZA201908550B (en) 2024-06-26
EP3654955A1 (fr) 2020-05-27
CA3069948A1 (fr) 2019-01-24
CR20190577A (es) 2020-01-29
CN110913843B (zh) 2022-09-13
KR102409102B1 (ko) 2022-06-16
JOP20200005A1 (ar) 2020-01-14
DOP2020000010A (es) 2020-02-28
UA125535C2 (uk) 2022-04-13
CL2020000120A1 (es) 2020-07-17
PH12020500120A1 (en) 2020-09-28
SG11201912482WA (en) 2020-02-27
WO2019018155A1 (fr) 2019-01-24
CN110913843A (zh) 2020-03-24
SA520410976B1 (ar) 2023-03-23
IL272044A (en) 2020-03-31
US20210137842A1 (en) 2021-05-13
AU2018301924A1 (en) 2019-12-19
BR112019028278A2 (pt) 2020-07-14

Similar Documents

Publication Publication Date Title
DK3688162T3 (da) Formuleringer
DK3529248T3 (da) Farmaceutiske sammensætninger
FR21C1059I2 (fr) Compositions pharmaceutiques
MA50541A (fr) Formulations pharmaceutiques
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
BR112016023628A2 (pt) composições farmacêuticas.
MA42303A (fr) Formulations pharmaceutiques
DK3634377T3 (da) Farmaceutisk formulering
MA46867A (fr) Formulations pharmaceutiques
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
MA45187A (fr) Combinaisons pharmaceutiques
MA49837A (fr) Compositions pharmaceutiques
MA44987A (fr) Formulations de médicaments améliorées
DK3583943T3 (da) Farmaceutisk sammensætning
MA44079A (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
IL304109A (en) Pharmaceutical preparations containing spinamide
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
ES2981002T3 (es) Formulación farmacéutica
DK3280447T3 (da) Farmaceutiske formuleringer
DK3302483T3 (da) Farmaceutiske sammensætninger og anvendelse deraf
DK3601277T3 (da) Farmaceutisk formulering
DK3609464T3 (da) Xanthohumolbaserede sammensætninger
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
DK3288933T3 (da) Oxindolforbindelser og farmaceutiske sammensætninger deraf